Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355

For the Children's Oncology Group (COG)

doi:10.3389/fimmu.2018.01641

Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355

For the Children's Oncology Group (COG)

Research output: Contribution to journal › Comment/debate

8 Scopus citations

Abstract

This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex's Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick's Foundation and COG SDC grant U10CA180899. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Original language	English
Article number	1641
Journal	Frontiers in Immunology
Volume	9
Issue number	JUL
DOIs	https://doi.org/10.3389/fimmu.2018.01641
State	Published - 16 07 2018
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu.

Keywords

Anti-GD2 chimeric antibody
Cytokine biomarkers
Cytokines
Immunotherapy
Neuroblastoma
Safety

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fimmu.2018.01641

Fingerprint

Dive into the research topics of 'Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355'. Together they form a unique fingerprint.

Cite this

For the Children's Oncology Group (COG) (2018). Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355. Frontiers in Immunology, 9(JUL), Article 1641. https://doi.org/10.3389/fimmu.2018.01641

For the Children's Oncology Group (COG). / Corrigendum : A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355. In: Frontiers in Immunology. 2018 ; Vol. 9, No. JUL.

@article{91efdf6c8161447789f2d2873255dbf6,

title = "Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355",

abstract = "This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) \# W81XWH-12-1-0427, by grant from the NIH (AY) \#5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex's Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick's Foundation and COG SDC grant U10CA180899. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.",

keywords = "Anti-GD2 chimeric antibody, Cytokine biomarkers, Cytokines, Immunotherapy, Neuroblastoma, Safety",

author = "\{For the Children's Oncology Group (COG)\} and Ozkaynak, \{M. Fevzi\} and Gilman, \{Andrew L.\} and London, \{Wendy B.\} and Arlene Naranjo and Diccianni, \{Mitchell B.\} and Tenney, \{Sheena C.\} and Malcolm Smith and Messer, \{Karen S.\} and Robert Seeger and \{Patrick Reynolds\}, C. and Smith, \{L. Mary\} and Shulkin, \{Barry L.\} and Marguerite Parisi and Maris, \{John M.\} and Park, \{Julie R.\} and Sondel, \{Paul M.\} and Yu, \{Alice L.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu.",

year = "2018",

month = jul,

day = "16",

doi = "10.3389/fimmu.2018.01641",

language = "英语",

volume = "9",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

number = "JUL",

}

For the Children's Oncology Group (COG) 2018, 'Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355', Frontiers in Immunology, vol. 9, no. JUL, 1641. https://doi.org/10.3389/fimmu.2018.01641

Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355. / For the Children's Oncology Group (COG).
In: Frontiers in Immunology, Vol. 9, No. JUL, 1641, 16.07.2018.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355

AU - For the Children's Oncology Group (COG)

AU - Ozkaynak, M. Fevzi

AU - Gilman, Andrew L.

AU - London, Wendy B.

AU - Naranjo, Arlene

AU - Diccianni, Mitchell B.

AU - Tenney, Sheena C.

AU - Smith, Malcolm

AU - Messer, Karen S.

AU - Seeger, Robert

AU - Patrick Reynolds, C.

AU - Smith, L. Mary

AU - Shulkin, Barry L.

AU - Parisi, Marguerite

AU - Maris, John M.

AU - Park, Julie R.

AU - Sondel, Paul M.

AU - Yu, Alice L.

PY - 2018/7/16

Y1 - 2018/7/16

N2 - This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex's Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick's Foundation and COG SDC grant U10CA180899. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

AB - This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex's Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick's Foundation and COG SDC grant U10CA180899. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

KW - Anti-GD2 chimeric antibody

KW - Cytokine biomarkers

KW - Cytokines

KW - Immunotherapy

KW - Neuroblastoma

KW - Safety

UR - https://www.scopus.com/pages/publications/85050163119

U2 - 10.3389/fimmu.2018.01641

DO - 10.3389/fimmu.2018.01641

M3 - 评论/辩论

AN - SCOPUS:85050163119

SN - 1664-3224

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

IS - JUL

M1 - 1641

ER -

For the Children's Oncology Group (COG). Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355. Frontiers in Immunology. 2018 Jul 16;9(JUL):1641. doi: 10.3389/fimmu.2018.01641

Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this